•Completed BLA submission seeking accelerated approval of nomlabofusp for adults and pediatric patients with FA; potential to be the first disease-modifying therapy to address root cause of disease
•Previously disclosed FDA alignment on key BLA elements, including willingness to consider skin frataxin as a potential novel surrogate endpoint
•Patients currently enrolling in FORWARD-FA, the global confirmatory Phase 3 study for nomlabofusp
•$128.7 million in cash, cash equivalents and marketable securities as of September 30, 2026, with projected cash runway into late Q2 2027
Bala Cynwyd, PA, November 16, 2026 – Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its third quarter 2026 operating and financial results.
“Completing the BLA submission for nomlabofusp marks a major milestone for Larimar and the Friedreich’s ataxia (FA) community,” said Carole Ben-Maimon, M.D., Chief Executive Officer of Larimar.